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motion was 8.4% and 8.8% respectively). Full results can be 
found in Table 1. 
Table 1: Data for the cases measured at 4mm and 10mm 
motion with variable rescanning,evaluated with D5-D95. 
RS=Rescan factor 
 
 
Figure 1: (Top) Central plane of target at 10 mm motion,with 
variable rescan factors (+static),normalised to mean dose of 
rescan factor=8 case (100% = 1.73 Gy). (Bottom) DVH 
corresponding to the above cases extracted three film 
measurement. 
 
Conclusions: Scaled,volumetric rescanning of PBS proton 
therapy has been shown to deliver clinically acceptable dose 
distributions in an anatomically realistic lung motion 
phantom,provided a large enough rescan factor is used. For 
single field delivery,8 times rescanning was found to be 
necessary for motions of 10 mm,with little or no re-scanning 
required for motion of 4 mm.  
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Purpose/Objective: This report of ASCENDE-RT* compares 
the efficacy of low-dose-rate prostate brachytherapy (LDR-
PB) to dose-escalated external beam radiation therapy (DE-
EBRT) for men with National Comprehensive Cancer Network 
(NCCN) intermediate- and high-risk prostate cancer.  
Materials and Methods: A total of 398 patients were accrued 
to a randomized trial at 6 institutions, stratified by risk group 
(276 high, 122 intermediate) and randomized (1:1) to one of 
two treatment arms. All patients had androgen deprivation 
therapy (ADT) for a total of 12 months using depot LHRH 
agonist injections and at least 4 weeks of oral anti-androgen 
coverage. After 8 month of neo-adjuvant ADT, all patients 
received four-field pelvic EBRT (46 Gy/23#). Those assigned 
to the DE-EBRT arm (N=200) continued with an additional 32 
Gy in 16# via a 2-phase, 3-d conformal technique without 
interruption in treatment. The men assigned to the LDR-PB 
arm (N=198) received an 125Iodine LDR-PB implant after a two 
week break (MPD = 115 Gy). Disease free survival (DFS) using 
the nadir+2 ng/mL (Phoenix) definition of biochemical failure 
was the primary endpoint. For actuarial analysis, time was 
calculated from the date of the first LHRH injection. No 
patients were excluded and all reported results are based on 
an intent-to-treat analysis. 
Results: Twelve major protocol violations occurred in each 
arm. The median follow up (FU) is 6.5 years. Compared to 
the DE-EBRT arm, men assigned to LDR-PB boost were more 
than twice as likely to remain disease free using the standard 
Phoenix definition for biochemical relapse (hazard ratio = 
0.473; 95% CI 0.292 - 0.765; P = 0.0022), with the 7-yr K-M 
DFS of 86% (LDR-PB) vs 75% (DE-EBRT). Employing a alternate 
(surgical-type) threshold of >0.2 ng/mL to define PSA 
relapse, resulted in a 7-yr K-M DFS estimate of 82% for men 
randomised to LDR-PB compared to only 39% for men assigned 
to DE-EBRT boost (p<0.0001). There have been 68 deaths in 
total resulting in a K-M overall survival (OS) estimate of 83% 
at 7-yrs; the most common cause of death was prostate 
cancer (N=18) followed by heart disease (N=14), and lung 
cancer (N=7). There have been 38 deaths among those men 
assigned to DE-EBRT, 13 of whom had recurrent prostate 
cancer including 11 with documented metastatic disease. By 
comparison, there have been 30 deaths among men assigned 
to LDR-PB; 7 of whom had recurrent prostate cancer and 
documented metastases. 
 
 
Conclusions: In multi-centre randomized setting, an LDR-PB 
boost demonstrated a large advantage over a DE-EBRT boost 
in relation to the primary endpoint (DFS). To date, OS and 
prostate cancer-specific survival do not appear to differ 
between arms. However, existing trends favour LDR-PB, 
suggesting differences in these survival endpoints may well 
emerge with longer FU.  
*ASCENDE-RT: Androgen Suppression Combined with Elective 
Nodal and Dose Escalated Radiation Therapy is an NCI 
registered trial (NCT00175396).  
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